Azafaros Media Release | March 24, 2022
"Second Orphan Drug Designation Supports Azafaros’ Strategy to Develop AZ-3102 as a Disease Modifying Treatment in a Range of Severe Rare Inherited Metabolic Disorders" Read the full article here: Article Link Announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for AZ-3102 Based on its mode of action, AZ-3102 has broad applicability in addressing these inherited metabolic disorders. "As we explore the broad potential of AZ-3102 a